Date Added: 08/02/2017
Date Updated: 08/02/2017
Bioresorbable vascular scaffolds for coronary artery disease
Specialties: Cardiovascular disease & vascular surgery
Technology Type: Devices
Stage of development: Established
Stage of EAA: Revised assessment
In 2015, a Technology Brief investigated the use of BVS for coronary artery disease (CAD). HealthPACT noted that BVS were more expensive than current comparative devices - bare-metal or drug-eluting stents - but had not as yet demonstrated clinical superiority to justify a higher premium. Consequently, HealthPACT recommended that the use of BVS in Australian clinical practice was not justified at that time.In response to the developing evidence on this device, the Brief recommended that the clinical and cost effectiveness of this technology be monitored for further evidence in 12 months. In line with this recommendation, the purpose of the current Update is to consider the evidence that has emerged since 2015, and to determine whether this new evidence may provide additional information to inform policy and funding decision making.
The currently available evidence raises some doubts as to whether patient outcomes with the BVS technology are equivalent in effectiveness and safety compared to those achieved in patients treated with conventional drug eluting stents. In addition, HealthPACT noted that the Absorb Bioresorbable Vascular Scaffold System is listed on the Prostheses List (AY045) at an equivalent price to drug eluting coronary artery stents, with a list price of $3,450, which is significantly higher than the negotiated price in the public sector.